Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast-conservation therapy for lymph node-negative, human epidermal growth factor receptor 2-positive breast cancer

Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer

(2011) Heather L. McArthur et al.   CANCER

Breast Conservation Therapy in Patients With Stage T1–T2 Breast Cancer

(2010) Carlos A. Perez   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Cancer Statistics, 2010

(2010) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Estrogen/Progesterone Receptor Negativity and HER2 Positivity Predict Locoregional Recurrence in Patients With T1a,bN0 Breast Cancer

(2010) Jeffrey M. Albert et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS

Management of small HER2-positive breast cancers

(2010) Susana Banerjee et al.   LANCET ONCOLOGY

Poor survival outcomes in HER2-positive breast cancer patients with low-grade, node-negative tumours

(2009) S M Tovey et al.   BRITISH JOURNAL OF CANCER

Clinical Relevance ofHER2Overexpression/Amplification in Patients With Small Tumor Size and Node-Negative Breast Cancer

(2009) Giuseppe Curigliano et al.   JOURNAL OF CLINICAL ONCOLOGY

Trastuzumab for Patients With Axillary-Node–Positive Breast Cancer: Results of the FNCLCC-PACS 04 Trial

(2009) Marc Spielmann et al.   JOURNAL OF CLINICAL ONCOLOGY

High Risk of Recurrence for Patients With Breast Cancer Who Have Human Epidermal Growth Factor Receptor 2–Positive, Node-Negative Tumors 1 cm or Smaller

(2009) Ana M. Gonzalez-Angulo et al.   JOURNAL OF CLINICAL ONCOLOGY

Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial

(2008) M. Untch et al.   ANNALS OF ONCOLOGY

Human Epidermal Growth Factor Receptor 2 Overexpression As a Prognostic Factor in a Large Tissue Microarray Series of Node-Negative Breast Cancers

(2008) Stephen Chia et al.   JOURNAL OF CLINICAL ONCOLOGY